Get started
Author

Sebastian Heinzmann

Observed names: S Heinzmann, S. Heinzmann
Institution: Roche (Switzerland)
ORCID: 0000-0002-2341-974X
Observed ORCID: 0000-0002-2341-974X
OpenAlex ID: A5011751380
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
2022 · Alexander Drilon, Chao-Hua Chiu, et al. · JTO Clinical and Research Reports · 114
PDF
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
2023 · Vivek Subbiah, Mimi I. Hu, et al. · Thyroid · 63
PDF
New molecules for the treatment of pain
2011 · Sebastian Heinzmann, Stephen B McMahon · Current Opinion in Supportive and Palliative Care · 22
Entrectinib in patients with ntrk fusion-positive (ntrk-fp) thyroid cancer: Updated data from startrk-2
2022 · Bowles Daniel W, Lyudmila Bazhenova, et al. · Endocrine Abstracts · 7
Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC).
2023 · Byoung Chul Cho, Chao-Hua Chiu, et al. · Journal of Clinical Oncology · 6
Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
2022 · George D. Demetri, Filippo De Braud, et al. · Clinical Cancer Research · 3
Data from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al. · 1
173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2
2022 · J. Lu, C.M. Blakely, et al. · Annals of Oncology · 1
Supplementary Data from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
PDF
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
PDF
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
PDF
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Data from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Supplementary Figure from Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
2023 · George D. Demetri, Filippo De Braud, et al.
Works count: 29
Citation count: 217
H-index: 5
I10-index: 3
Year
Topic
Type